收藏切换
Clinical comprehensive evaluation of proprotein convertase subtilisin kexin 9 monoclonal antibodies based on the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition)
收藏切换
Juan-juan MA, Jie CHENG, Xiao-yu JU, Jie-wei SUN, Yun-huan WANG*
Chinese Journal of New Drugs | 2026, 35(14) : 1545 - 1552
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(14): 1545-1552
Clinical comprehensive evaluation of proprotein convertase subtilisin kexin 9 monoclonal antibodies based on the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition)
Full
Juan-juan MA, Jie CHENG, Xiao-yu JU, Jie-wei SUN, Yun-huan WANG*
Affiliations
  • Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang 050011, China
Published: 2026-07-30 doi: 10.20251/j.cnki.1003-3734.2026.14.013
Outline
收藏切换
Objective:

To conduct a comprehensive analysis of proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibodies based on a multi-dimensional evaluation method, providing a reference for clinical medication selection and drug selection in medical institutions.

Methods:

Referring to the evaluation system in the Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition), with appropriate adjustments to some scoring criteria, a quantitative assessment was conducted on six PCSK9 monoclonal antibodies available in the domestic market from five aspects: pharmaceutical characteristics, efficacy, safety, economy, and other attributes. The recommendation grades were determined based on the scoring results.

Results:

The quantitative scoring results, ranked from high to low, were as follows: evolocumab (79.31 points), alirocumab (74.85 points), tolersimab (73.86 points), recaticimab (71.95 points), ongericimab (70.9 points), and ebronucimab (70.88 points).

Conclusion:

All six PCSK9 monoclonal antibodies demonstrated good lipid-lowering efficacy. Among them, evolocumab, alirocumab, and tolersimab are strongly recommended, while the others are weakly recommended.

PCSK9 monoclonal antibody  /  drug selection  /  evolocumab  /  alirocumab  /  tafolecimab  /  ebronucimab  /  ongericimab  /  recaticimab
马娟娟, 程杰, 鞠晓宇, 孙杰威, 王云环. 基于《中国医疗机构药品评价与遴选快速指南(第二版)》的前蛋白转化酶枯草溶菌素9单克隆抗体临床综合评价. 中国新药杂志, 2026 , 35 (14) : 1545 -1552 . DOI: 10.20251/j.cnki.1003-3734.2026.14.013
Juan-juan MA, Jie CHENG, Xiao-yu JU, Jie-wei SUN, Yun-huan WANG. Clinical comprehensive evaluation of proprotein convertase subtilisin kexin 9 monoclonal antibodies based on the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the 2nd edition)[J]. Chinese Journal of New Drugs, 2026 , 35 (14) : 1545 -1552 . DOI: 10.20251/j.cnki.1003-3734.2026.14.013
Year 2026 volume 35 Issue 14
60
9
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.14.013
  • Online Date:2026-10-26
  • Published:2026-07-30
Article Data
Affiliations
History
  • Accepted:2026-03-10
Funding
Affiliations
    Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang 050011, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.14.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT